ARPANSA has also commenced an independent environmental monitoring program. The independent measurements obtained by ARPANSA are compared against the values measured by ANSTO. This is done to provide additional assurance that the results reported by ANSTO are accurate and the community and environment are protected from harmful effects of radiation.
In June 2018, ARPANSA issued a direction to its licence holder, the Australian Nuclear Science and Technology Organisation (ANSTO), to initiate an independent review of its approach to occupational radiation safety at its nuclear medicine facility operated by ANSTO Health, now known as Health Products.
Part of ARPANSA’s role is the regulation of all Commonwealth entities that use radiation. Regulation ensures compliance with the Australian Radiation Protection and Nuclear Safety Act 1998 and associated Regulations (2018) and is supported by a series of regulatory guides.
ARPANSA’s CEO, Dr Carl-Magnus Larsson has issued a licence to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine Molybdenum-99 (Mo-99) Facility (the ANM Facility).
On Monday 26 February 2018 a report by the CEO of ARPANSA, Dr Carl-Magnus Larsson, was tabled in Parliament addressing the radiation exposure of a worker at the Australian Nuclear Science and Technology Organisation (ANSTO) Health radiopharmaceuticals production facility at Lucas Heights.
The matter considered in this report is a radiation exposure of a worker on 22 August 2017 at the Australian Nuclear Science and Technology Organisation (ANSTO) Health radiopharmaceuticals production facility at Lucas Heights, NSW, which exceeded the relevant statutory dose limit.
ARPANSA respectfully acknowledges the Traditional Owners and Custodians of Country throughout Australia and their continuing connection to land, waters and community. We pay our respect to Aboriginal and Torres Strait Islander Peoples, their cultures, and to Elders past and present.